Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.34 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30834457 | 1.00 | ENPP2 (0.38) | ENPP2PARP1KDM4ETDP1MMP3 | |
| SCHEMBL29183394 | 0.81 | MEN1 (0.52) | PARP1IDO1LOXLOXL2MEN1 | |
| SCHEMBL3676475 | 0.79 | ENPP2 (0.40) | ENPP2KDM4ETDP1MMP3LOXL2 | |
| SCHEMBL16361032 | 0.78 | ATM (0.41) | PARP1CSNK2A1MEN1KMT2A | |
| SCHEMBL29841095 | 0.76 | GRM5 (0.46) | ENPP2KDM4ETDP1MMP3TGFBR1 | |
| SCHEMBL13183449 | 0.76 | ENPP2 (0.38) | ENPP2KDM4ETDP1MMP3LOX | |
| SCHEMBL1925278 | 0.76 | GRM5 (0.46) | ENPP2KDM4ETDP1MMP3TGFBR1 | |
| SCHEMBL9280722 | 0.76 | RECQL (0.57) | ENPP2KDM4ETDP1MMP3LOX | |
| SCHEMBL29894545 | 0.76 | LOXL2 (0.57) | ENPP2KDM4ETDP1MMP3IDO1 | |
| SCHEMBL897832 | 0.76 | LOXL2 (0.57) | ENPP2KDM4ETDP1MMP3IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-10053465-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | INCYTE CORPORATION (US) | 2018-08-21 | — | — | US | disclosed |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2017-03-02 | — | — | US | disclosed |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | INCYTE CORPORATION | 2017-03-02 | — | — | US | disclosed |
| WO-2011056440-A1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056440-A1 | HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101472921-A | Pyridylisoxazole derivative | ASKA PHARM CO LTD (JP) | 2009-07-01 | — | — | CN | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20050107437-A1 | comprising pyridylalkynes used as preemergence and postemergence herbicides | SYNGENTA CROP PROTECTION, INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1453807-A2 | NOVEL HERBICIDES | Syngenta Participations AG (CH) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050087-A2 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | TP53, CASP3, BAX | ENPP2 457/4885PARP1 491/4885KDM4E 1620/4885 |
| US-11136326-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | ENPP2 1981/4885PARP1 1006/4885KDM4E 739/4885 |
| US-20190031663-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | ENPP2 1981/4885PARP1 1006/4885KDM4E 739/4885 |
| US-10053465-B2 | Pyrrolopyrimidine derivatives as TAM inhibitors | FLT3, MERTK, MIF | ENPP2 1981/4885PARP1 1006/4885KDM4E 739/4885 |
| US-20200181151-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | ENPP2 1981/4885PARP1 1006/4885KDM4E 739/4885 |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | ENPP2 1255/4885PARP1 2480/4885KDM4E 1377/4885 |
| US-20170057965-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS | FLT3, MERTK, MIF | ENPP2 1981/4885PARP1 1006/4885KDM4E 739/4885 |
| US-20050107437-A1 | comprising pyridylalkynes used as preemergence and postemergence herbicides | DDT, CHRM1, CYP4X1 | ENPP2 4436/4885PARP1 3091/4885KDM4E 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.